/NMRA
NMRA Stock - Neumora Therapeutics, Inc. Common Stock
Healthcare|BiotechnologyNASDAQ
$1.75+1.74%
+$0.03 (+1.74%) • Dec 19
59
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.57
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.0
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+328.6%upside
Target: $7.50
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for NMRA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.73 – $1.77
TARGET (TP)$7.50
STOP LOSS$1.61
RISK/REWARD1:41.1
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta3.16
52W High$11.57
52W Low$0.61
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | $-668,000 | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-263,464,000 | $-188,194,000 | $-135,870,000 | $-237,323,000 | $-95,518,000 |
| Net Income | $-243,787,000 | $-235,925,000 | $-130,904,000 | $-237,312,000 | $-99,272,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-1.53 | $-1.49 | $-0.86 | $-1.56 | $-0.65 |
Company Overview
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
10
67%
Hold / Neutral
4
27%
Sell / Underperform
1
7%
Analyst Consensus🟡 Mixed
10 Bullish5 Neutral/Bearish
Price Targets
$17
Average Target
↑ 850.0% Upside
Now
$1
Low
$17
Average
$30
High
Based on 16 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 1st 2025 | RBC Capital Mkts | Upgrade | Outperform | $7 |
| October 27th 2025 | Guggenheim | Upgrade | Buy | $14 |
| September 16th 2025 | JP Morgan | Downgrade | Underweight | - |
| April 2nd 2025 | BofA Securities | Downgrade | Underperform | $1 |
| March 10th 2025 | William Blair | Downgrade | Market Perform | - |
| March 7th 2025 | Guggenheim | Downgrade | Neutral | - |
| March 7th 2025 | Stifel | Downgrade | Hold | $2← $6 |
| January 2nd 2025 | RBC Capital Mkts | Downgrade | Sector Perform | $4← $29 |
| November 5th 2024 | JP Morgan | Downgrade | Neutral | $15← $18 |
| October 1st 2024 | H.C. Wainwright | Initiation | Buy | $30 |
| July 22nd 2024 | Needham | Initiation | Buy | $23 |
| July 8th 2024 | Mizuho | Initiation | Outperform | $20 |
| December 12th 2023 | Deutsche Bank | Initiation | Hold | $13 |
| October 10th 2023 | BofA Securities | Initiation | Buy | $18 |
| October 10th 2023 | William Blair | Initiation | Outperform | $26 |
Earnings History & Surprises
NMRABeat Rate
33%
Last 9 quarters
Avg Surprise
-24.1%
EPS vs Estimate
Beats / Misses
3/5
1 met exactly
Latest EPS
$-0.35
Q4 2025
EPS Surprise History
Q1 24
-9.2%
$-0.71vs$-0.65
Q2 24
+2.9%
$-0.34vs$-0.35
Q3 24
0.0%
$-0.37vs$-0.37
Q4 24
-18.4%
$-0.45vs$-0.38
Q1 25
+19.6%
$-0.37vs$-0.46
Q2 25
-5.0%
$-0.42vs$-0.40
Q3 25
+13.2%
$-0.33vs$-0.38
Q4 25
-2.9%
$-0.35vs$-0.34
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 27, 2026 | — | — | — | — |
Q1 2026 | Mar 2, 2026 | $-0.34 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.34 | $-0.35 | -2.9% | ✗ MISS |
Q3 2025 | Aug 6, 2025 | $-0.38 | $-0.33 | +13.2% | ✓ BEAT |
Q2 2025 | May 12, 2025 | $-0.40 | $-0.42 | -5.0% | ✗ MISS |
Q1 2025 | Mar 3, 2025 | $-0.46 | $-0.37 | +19.6% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-0.38 | $-0.45 | -18.4% | ✗ MISS |
Q3 2024 | Aug 6, 2024 | $-0.37 | $-0.37 | 0.0% | = MET |
Q2 2024 | May 7, 2024 | $-0.35 | $-0.34 | +2.9% | ✓ BEAT |
Q1 2024 | Mar 7, 2024 | $-0.65 | $-0.71 | -9.2% | ✗ MISS |
Q4 2023 | Nov 1, 2023 | $-0.36 | $-1.14 | -216.7% | ✗ MISS |
Q2 2023 | Jun 30, 2023 | — | $-0.25 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.23 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.19 | — | — |
Q3 2022 | Sep 30, 2022 | — | $-0.19 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.20 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-0.28 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.18 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-1.17 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.11 | — | — |
Latest News
Neumora Therapeutics shares are trading higher after RBC Capital upgraded the stock from Sector Perform to Outperform and raised its price target from $4 to $7.
📈 PositiveBenzinga•Dec 1, 2025, 12:57 PM
RBC Capital Upgrades Neumora Therapeutics to Outperform, Raises Price Target to $7
📈 PositiveBenzinga•Dec 1, 2025, 11:33 AM
Stifel Maintains Hold on Neumora Therapeutics, Raises Price Target to $3
➖ NeutralBenzinga•Nov 17, 2025, 01:52 PM•Also:
NMRA stock has given up its prior loss. Neumora Therapeutics shares were trading lower after the company reported worse-than-expected Q3 EPS results.
📉 NegativeBenzinga•Nov 6, 2025, 04:35 PM
Neumora Therapeutics shares are trading lower after the company reported worse-than-expected Q3 EPS results.
📉 NegativeBenzinga•Nov 6, 2025, 01:55 PM
Neumora Therapeutics Q3 EPS $(0.35) Misses $(0.33) Estimate
📉 NegativeBenzinga•Nov 6, 2025, 12:22 PM
Needham Maintains Buy on Neumora Therapeutics, Raises Price Target to $8
📈 PositiveBenzinga•Oct 28, 2025, 11:41 AM
Guggenheim Upgrades Neumora Therapeutics to Buy, Announces $14 Price Target
📈 PositiveBenzinga•Oct 27, 2025, 12:20 PM
Neumora Begins Phase 1 Trial for New Schizophrenia Drug Candidate NMRA-898
📈 PositiveBenzinga•Oct 27, 2025, 11:11 AM
Neumora Announces Preclinical Data For NMRA-215, Showing Weight Loss Of Up To 19% As Monotherapy With Semaglutide-Like Induction; Plans To Initiate Phase 1 Clinical Study In Q1 2026
📈 PositiveBenzinga•Oct 27, 2025, 10:36 AM
JP Morgan Downgrades Neumora Therapeutics to Underweight
📉 NegativeBenzinga•Sep 16, 2025, 10:39 AM•Also:
Frequently Asked Questions about NMRA
What is NMRA's current stock price?
Neumora Therapeutics, Inc. Common Stock (NMRA) is currently trading at $1.75 per share. The stock has moved +1.74% today.
What is the analyst price target for NMRA?
The average analyst price target for NMRA is $7.50, based on 1 analyst.
What sector is Neumora Therapeutics, Inc. Common Stock in?
Neumora Therapeutics, Inc. Common Stock operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is NMRA's market cap?
Neumora Therapeutics, Inc. Common Stock has a market capitalization of $0.29 billion, making it a small-cap company.
Does NMRA pay dividends?
No, Neumora Therapeutics, Inc. Common Stock does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorADCT
ADC Therapeutics S.A.
$3.73
Mkt Cap: $0.4B
ALMS
Alumis Inc. Common Stock
$11.29
Mkt Cap: $1.2B
AUTL
Autolus Therapeutics plc
$1.63
Mkt Cap: $0.4B
BCYC
Bicycle Therapeutics plc
$6.87
Mkt Cap: $0.5B
FDMT
4D Molecular Therapeutics, Inc.
$8.68
Mkt Cap: $0.4B
FULC
Fulcrum Therapeutics, Inc.
$12.28
Mkt Cap: $0.7B
LXRX
Lexicon Pharmaceuticals, Inc.
$1.17
Mkt Cap: $0.4B
OMER
Omeros Corporation
$9.60
Mkt Cap: $0.7B
PRTA
Prothena Corporation plc
$9.21
Mkt Cap: $0.5B
RAPT
RAPT Therapeutics, Inc.
$33.81
Mkt Cap: $0.6B
Explore stocks similar to NMRA for comparison